Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: SLAS Discov. 2018 May 11;23(8):842–849. doi: 10.1177/2472555218775055

Figure 4.

Figure 4

Analysis of selected compounds from 1536-well pilot screening of the NCI and FDA collections on GBM6 and U87 cells under different culture conditions. Various concentrations of selected compounds (10-point, 1:3 serial dilutions, starting at 5 μM concentration) were used to treat GBM6 spheroids grown on 3D (A), GBM6 grown on laminin-coated plates in order for them to grow on 2D (B), GBM6 differentiated using 10% FCS-containing medium (C) or the established glioblastoma cell line U87 (D). (E) A summary of the LogEC50 of the different conditions for each indicated cell type and condition is presented including the fold difference of the EC50 of each condition vs the condition that was used for the screening (GBM6 spheroids grown on 3D) is included in the table on the right.